The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -165,361 | -353,348 |
| Share-based compensation | 0 | 0 |
| Non-cash interest on convertible notes | 18,483 | 36,365 |
| Interest expense on loan payable | 0 | 0 |
| Accretion to redemption value on convertible notes | 0 | 0 |
| Prepaid expenses and other current assets | 19,421 | -22,476 |
| Accounts payable | -49 | -1,057 |
| Accrued compensation | 123,111 | 244,346 |
| Accrued expenses and other | 21,415 | -10,218 |
| Net cash used in operating activities | -21,822 | -61,436 |
| Proceeds from issuance of loan payable | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 |
| Net change in cash and cash equivalents | -21,822 | -61,436 |
| Cash and cash equivalents at beginning of period | 115,019 | - |
| Cash and cash equivalents at end of period | 31,761 | - |
Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. (CPMV)